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Eighty-two percent (82%) of patients initiating hemodialysis
in the United States in 2006 did so with a catheter as the
functioning access. Even in patients who have been followed
by nephrologists for 6 months or more, 74% of patients
initiated dialysis with a catheter. This is a multifactoral
problem that requires attention and solutions from all
stakeholders, including the nephrologist, the vascular
surgeon, the hospital, and the insurance industry, as well as
the patient and family. We propose a series of specific
proposals that include a process for the timely referral and
timely placement of a permanent access based on the
patient’s estimated or measured glomerular filtration rate
(GFR), and a ‘pay-for-performance’ measure for vascular
surgeons and nephrologists who admit patients with
functional permanent accesses; such pay for performance
would place a higher value for patients who are admitted
with a functional arteriovenous (AV) fistula than for patients
who are admitted with an AV graft. We also propose that
hospitals develop a less permissive process for placement of
PICC (peripherally inserted central catheters) lines in patients
with GFR o60ml/min and to consider surgery for access
placement as ‘urgent’. Finally, a more proactive educational
process for patients and their families, including an ‘informed
non-consent’ for patients who defer placement of a
permanent access needs to be considered. The morbidity,
mortality, and health-care costs associated with prolonged
catheter use mandate urgent attention to this problem.
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More than 10 years ago, we authored an editorial entitled
‘Hemodialysis Access Failure: A Call to Action’.1 We identified
the high prevalence of grafts (70% in 1993) and subclavian
catheters, particularly in incident patients, as a problem
requiring a concerted action plan. Since that time, cumulative
effects from the development of clinical practice guidelines
and clinical performance measures, and implementation of
the Fistula First breakthrough initiative by the Centers for
Medicare and Medicaid Services (CMS) have clearly im-
pacted hemodialysis access management. Currently, 47% of
prevalent patients in the United States have a native
arteriovenous (AV) fistula, whose use has consistently been
associated with improved morbidity and mortality.2,3 The use
of subclavian catheters has also greatly diminished. This
represents a very significant accomplishment, for which
nephrologists, surgeons, CMS, and other stakeholders can
take pride.4,5
Nevertheless, these important improvements in clinical
care have not been achieved without unintended conse-
quences. Indeed, this substantial improvement in AV fistula
placement has, unfortunately, also been accompanied by a
notable increase in the percentage of prevalent patients with
catheters; currently, 28% of all patients in the United States
have permanent (490 days) catheters which is, with a few
exceptions (such as Canada and Belgium), much higher than
the rest of the world.6 The proportion of hemodialysis
patients with any lifetime catheter exposure is also extra-
ordinarily high.7,8 Even more alarming, according to the
United States Renal Data System (USRDS),9 82% of patients
initiating hemodialysis in the United States in 2006 did so
with a catheter as the functioning access (Figure 1). This is
alarming as catheter-related bacteremia, occurring at a
frequency ranging from 1.5 to 5.5 episodes per 1000-catheter
days, remains a morbid and often lethal complication.10
Moreover, earlier use of catheters is associated with a 60–70%
higher risk of subsequent fistula failure.11
In the face of overwhelming evidence about the increased
risks associated with catheters, we wish to examine the factors
that are leading to increasing use of catheters, particularly in
incident patients. We also explore potential solutions that
require collaborative efforts from many segments of health
care. At the outset, it should be stated that this is a
multifactorial problem, with contributions from the structure
of the health-care system in the United States, surgical
expertise and interest, lack of adequate knowledge regarding
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the biology of AV fistula maturation, and a shortage of
adequately designed and powered controlled trials evaluating
interventions designed to improve access outcomes. Never-
theless, it is important to acknowledge that as nephrologists,
we share a major part of the responsibility for these
outcomes, and along with our surgical colleagues share the
responsibilities to develop a continuous quality improvement
process to reduce the prevalence of catheters, particularly in
incident patients.
A MULTIFACTORIAL PROBLEM
Role of the nephrologist
Much has been written about delayed referral to nephro-
logists by internists or other medical specialties of patients
with moderate-to-severe kidney disease. Several factors,
including the lack of recognition of the relationships between
serum creatinine level, muscle mass, and actual glomerular
filtration rate (GFR), have been described in several
publications as a cause for the delayed referral to nephro-
logical care and will not be discussed here further.12,13 What
is often not mentioned is that a common reason cited by
internists for not referring patients with advanced chronic
kidney disease (CKD) in a timely manner to nephrologists is
‘lack of knowledge of criteria for referral’.14
But even when referral is timely, busy nephrologists divide
their time between office practice, hospital rounds, and
administrative and rounding duties at the dialysis unit. It is
therefore not uncommon for nephrology practices to delay
accepting ‘non-urgent’ referrals for several months or initially
accepting a referral of a patient with early-stage CKD, only to
transfer their care back to the referring physician with the
recommendation to continue their follow-up of the patient
and refer them back only when ‘creatinine is 6–7 mg/dl’. The
additional delay in evaluation shortens the window of time
available to establish accurate diagnosis, and perhaps more
importantly shortens the time to develop a rapport with the
patient that encourages the patient to accept their diagnosis,
the possible or likely need for renal replacement therapy, and
the nephrologist’s recommendation for a permanent access in
preparation for eventual dialysis.
Delayed acceptance of referred CKD patients is only one
aspect of the role of the nephrologist in this high catheter rate
in incident patients. According to the USRDS data, 60% of
incident patients are reported to receive care from nephrol-
ogists before the onset of end-stage renal disease.9 However,
even for patients who have been followed by a nephrologist
before their initiation to dialysis for 6 months or more, 75%
still initiated dialysis with a catheter, and only 20% of such
patients initiated dialysis with a fistula (Figure 2).9 Even in
patients with polycystic kidney disease, who are generally
referred early to nephrologists because of family history and
have a more predictable rate of kidney function loss, a
catheter is used in 50% of such patients initiating dialysis9
(Figure 3).
Undoubtedly, almost every nephrologist who provides
medical care to CKD patients mentions the need for a
permanent access at some point in the process of care, and
many do discuss the poor outcomes associated with the use
of catheters. Nevertheless, judging from the 75% of patients
who have been followed by a nephrologist but who still
initiate dialysis with a catheter, it is clear that such
recommendations are not always ‘heard’ or ‘understood’ by
the patient and/or their families, often because the recom-
mendation is not tailored to the ability of the patient to
comprehend; a complicating factor in this patient–nephrol-
ogist interaction is the difficulty in accurately predicting the
rate of progression of renal failure and the complex events of
‘acute on chronic’ renal injury that often precipitates the
need to start dialysis urgently.
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Figure 1 |Vascular-access use at initiation of dialysis. Eighty-
two percent of patients have a catheter at first outpatient
dialysis.36
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Figure 2 |Vascular access at initiation of dialysis for patients
with X6 months of follow-up by nephrologists. Seventy-five
percent of such patients have a catheter at first outpatient
dialysis.36 Glomeruloneph, glomerulonephritis.
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Finally, the lack of a structured education or training in
most Renal Fellowship programs about the placement and/or
cannulation of access results in a life-long knowledge deficit
that burdens most nephrologists’ ability to judge the success
and suitability of access cannulation.
Patient-related factors
The progression of kidney failure in many patients is
relatively slow and may occur over several months or years;
moreover, many patients with known CKD have expectations
that improved blood pressure and glycemic control may slow
or halt the progression of disease. CKD patients who are
referred to the ‘kidney specialist’ naturally expect that this
specialist will reverse or stop the progression of the disease.
All these factors contribute to the resistance that many
patients express when faced with the prospect of having a
permanent access placed in preparation for dialysis.
Nephrologists are also aware of the high mortality rate of
patients with CKD stages 3–4, and the risk of premature
cardiovascular deaths as a competitive risk for progression
from CKD to end-stage renal disease.15,16 In many elderly
patients, with multiple comorbidities, the nephrologist and
the patient’s family are reluctant to ‘impose’ another
procedure (i.e., surgery for a permanent access) on the
patient and instead elect to ‘watch and wait.’ However, recent
data suggest that this ‘competitive risk’ of cardiovascular
mortality is more applicable to non-referred patients, and
may not apply to patients who are referred to nephrolo-
gists.17,18 Indeed, for most patients, the potential complica-
tions from the surgical placement of a fistula in the forearm
are significantly less than the risk of catheter placement and
initiation of dialysis with a catheter.19
Perhaps an additional component of this reluctance by the
nephrologist to strongly advocate or insist on the timely
placement of a permanent access is the general expectation,
by both the patient and the nephrologist, that the loss of
kidney function is an orderly, gradual process, and therefore
recommendations for a permanent access may await the
‘next’ visit, usually in 3–4 months.16,20 Unfortunately, for
many patients, kidney disease progression, particularly in
CKD stage 4 or 5, tends to be erratic and difficult to predict.
Many CKD patients develop the need for dialysis initiation
acutely, in conjunction with an intercurrent illness.21,22 This
may partly explain the cyclical nature of dialysis initiation,
which peaks in the early months of the year (January–March)
when acute respiratory infectious events are more common
and has its nadir during the summer months, when such
infections are less prevalent.
Availability of patient educational programs
The progression of renal failure to a point where dialysis
initiation becomes imminent requires a different type of
patient–physician interaction. In the setting of advanced
CKD, patients require input from dietitians, social workers,
and nurse educators in addition to nephrologists. Such a
multi-specialty supportive education effort is often not
feasible in the setting of a busy practice and unfortunately
often does not occur. To the extent they exist, such programs
often do not include discussion of timely access placement,
and are generally not reimbursed by health insurance.
Hopefully, the kidney disease education provisions in
the recent ‘Medicare Improvements for Patients and
Providers Act’ (MIPPA) legislation will provide improved
reimbursement for this worthwhile effort and facilitate
education about the various treatment options available, as
well as the necessity of timely vascular access placement for
those who are likely to start hemodialysis. Ideally, such timely
educational programs should incorporate the vascular
surgeon who may explain the surgical procedure of fistula
placement.
Role of the vascular surgeon
The creation of an AV access may be considered by vascular
surgeons intellectually and technically as not challenging and
‘low priority.’ Partly because of this, creation of a vascular
access is not a procedure that many surgical residents are
trained to perform and few, if any, have enough experience to
perform them well in the United States. Although CMS and
most end-stage renal disease networks can track the
percentage of patients who initiate dialysis with fistula by
nephrologist, there is no national or regional tracking of
surgical outcomes by surgeons, hospitals, or by access centers.
A number of nephrology practices have developed their own
tracking tools of surgical outcomes and have channeled their
referrals to the most successful surgeons, with improved
patient outcomes. Finally, although the advantages of vein
mapping in guiding and assessing the feasibility of access
placement, and determining its optimal location has been
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Figure 3 |Vascular access utilization by cause of end-stage
renal disease. Even in patients with cystic disease, who have a
predictable loss of kidney function, catheters are used to initiate
60% of such patients. Glomeruloneph, glomerulonephritis.
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well established in several studies, vein mapping is not always
performed routinely before surgery.23–25
Another reason for delay by the vascular surgeon is that
many patients who are younger than 65 years old
(approximately 50% of the end-stage renal disease popula-
tion), and therefore not yet eligible for Medicare benefits,
may not have adequate alternative insurance coverage for the
procedure especially if the condition is determined to be ‘pre-
existing.’ In such cases, the surgeons often elect to delay the
surgical placement of a permanent access until the patient
initiates dialysis and becomes Medicare eligible (after 90 days
from dialysis initiation).
From surgical creation to maturation
Primary failure rate for AV fistulae remain extraordinarily
high (approximately 50–60%) in North America.26,27 In the
recently reported NIH funded Dialysis Access Consortium
randomized clinical trial comparing the use of clopidogrel
with placebo to maintain AV fistula patency, the remarkable
finding is that approximately 60% of fistulae fail to mature,
whether or not clopidogrel was administered (even though
the early thrombosis rate was significantly lower in the
clopidogrel-treated group).28,29 Almost half of all AV fistulae
will require at least one additional surgical procedure to
achieve adequate anatomy for successful repetitive cannula-
tion with two needles.30 Thus, a realistic time frame for a
fistula to be ready for cannulation is approximately 6 months,
with active follow-up of the fistula and if necessary, repeat
surgical intervention.31 The slow maturation time-frame for
fistulae may be one of the factors explaining not only the
high prevalence of catheters in patients initiating dialysis, but
also the persistence of catheters (52%) at 90 days after
initiating dialysis.
Even when an AV fistula is placed in patients with CKD
stages 4–5, but does not enlarge and ‘arterialize’ enough for
placement of two needles in a reasonable time (from 6 to 8
weeks), surgeons are often reluctant to intervene to ligate
tributaries or to re-anastomose the artery to a larger vein,
preferring instead to ‘wait it out.’32 Indeed, the time to
cannulation of fistulas exceeds 85 days in 82% of patients and
is between 43 and 85 days for 71% of patients in the United
States, much longer than what is observed by the Dialysis
Outcomes Practice patterns study in other countries.33,34
This often results in patients developing the need for dialysis
initiation before the fistula is mature enough for cannulation,
again leading to the use of a catheter as ‘bridge’ therapy. If
‘maturing’ fistulas are included in the tally, the percentage of
incident patients increases from 13% with a usable fistula to
30% with an available, but not yet ready to be used, fistula.
The hospital setting
Many patients who eventually reach a vascular surgeon for
placement of an access have had multiple medical and
surgical interventions. As a consequence, veins and distal
arteries (radial) have often been ‘used up’ or sclerosed.
Placement of peripherally inserted central catheter lines has
become routine in hospitalized patients, and contributes to
venous sclerosis. In such patients, an AV fistula, even an upper
arm AV fistula, may be much more difficult to create and
requires more surgical time and technical skills than that may
be available. Central stenosis, most often associated with earlier
placement of catheters, has been reported in 40% of patients
who undergo vein mapping or venography. In such cases where
the surgical procedure is more complicated, the expectation of
the nephrologist and the patient for a functional AV fistula may
well be a factor in the surgeon’s decision to delay specific
activity, so that the placement of a catheter or a graft (instead of
a fistula) become inevitable. We have previously recommended
that although a fistula is by far the preferred type of access, a
graft that matures within 2–3 weeks is a better option for
patients who are not likely to have a successful fistula, as an
intermediate step to eventual fistula placement.35
An additional complicating factor is that under Diagnosis-
Related Group rules for hospital reimbursement for Medicare
eligible patients, the placement of a catheter for dialysis
initiation prevents additional reimbursement for surgical
placement of an AV fistula in the same hospital admissions.
This also results in delays in the placement of a permanent
access in patients with ‘acute on chronic’ renal failure.
Role of the insurance industry
Remarkably, a substantial proportion of incident dialysis
patients, registered in two large insurance databases (Medstat
and Ingenix i3), have not had a measurement of creatinine or
been referred to a nephrologist in the 6 months before
initiation of dialysis36 (Figure 4). This may reflect restrictions
on laboratory testing and strict criteria for referral to
specialists imposed by many of these insurance companies.
It may also reflect the reality that even though the annual
costs of patients on dialysis is high, patients with private
insurance have only a limited time (currently 30 months,
called ‘Medicare Secondary Payer’ period) during which they
bear such costs. This time limit in their financial exposure, as
well as the short lifespan of many insurance companies
(because of mergers or consolidation), may be a factor for the
lack of focus in this otherwise expensive treatment. Finally,
the nonlinear relationship between creatinine measurement
and assessment of renal function may be an additional factor.
A MULTIFACTORIAL SOLUTION
We propose below a wide range of solutions to reduce the use
of catheters and increase the likelihood of a functional fistula in
the patient initiating dialysis. However, it should be noted that
a central tenant of a quality improvement project is to limit the
number of projects or ideas that need to be acted on, to
appropriately evaluate the success of each. Thus, we advocate
that such solutions be implemented in a stepwise manner.
Patient and family education
The interaction and the relationship between a CKD patient
who is approaching the need for dialysis and the nephrologist
is often complex and the recommendation by the nephrologist
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for placement of a permanent access in preparation for
initiation of dialysis is often perceived by both parties as an
‘admission of defeat.’ One potential solution is to have
educational settings for patients and their families in a
relaxed, unemotional setting in which CKD patients hear
about the medical criteria that determines the time of referral
for vascular access placement (Table 1). Education can focus
on objective parameters such as calculated or measured GFR,
the numerous advantages of having a ‘patient friendly’
permanent access (i.e., AV fistula) before initiation of dialysis,
a description of the procedure, the risks of dialysis with a
catheter, and the other treatment options available to the
patient ranging from transplantation, home dialysis (or
peritoneal dialysis (PD)), self-care dialysis, incenter dialysis,
and including the option of no renal replacement therapy.
Such an education program may allow not only the patient
but also importantly the patient’s family to be informed
about the available options and the many advantages of a
permanent access before to initiation of dialysis. In these
settings, patients and their families should be encouraged to ask
questions to help understand and appreciate the importance
and timeliness of recommendations, which should include
strong recommendations about timely placement of a
permanent access. Hopefully, the availability of adequate
payment for such educational efforts by the MIPPA legislation
will facilitate development of such programs nationally.
Timely placement of a permanent access using GFR
A potential guiding algorithm for the planning and
placement of a permanent access is the ‘30-20-10’ GFR-
based criteria for the planning and placement of a permanent
access37,38 (Table 1). In brief, this algorithm, which can also
be used by referring physicians as criteria for initial referral,
recommends the following:
K At a GFR of p30 ml/min, an educational program
highlighting treatment options and the need for perma-
nent access is initiated. If patients with such GFRs are not
actively followed by a nephrologist already, then the
‘referral criteria’ or ‘best practice’ expectations would be
to refer such patients to nephrological care no later than a
GFR of 30 ml/min and preferably earlier when CKD is
established. Several nephrology practices also recommend
that patients with GFR o30 ml/min wear a ‘medic-alert
bracelet’ that alerts health-care workers to save the veins
in that arm, and avoid PICC lines or other indwelling
intravenous catheters.
K At a GFR ofp20 ml/min, strongly consider placement of
a permanent access in patients who elect hemodialysis,
allowing time to assess AV fistula maturation and
secondary intervention if needed. A realistic time frame
for fistula maturation (including possible revisions) is no
less than 4–6 months.31 Referral to a qualified (i.e., with
good outcomes) vascular surgeon and if appropriate,
bilateral vein mapping is recommended.
K At a GFR of p10 ml/min, a mature fistula (or a PD
catheter) should be in place for possible initiation of
dialysis treatment.
Nephrologists increasingly need to be proactive in
educating their medical colleagues during formal and
informal hospital rounds about recommended ‘best practices’
in the care of patients with advanced CKD, including the
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Figure 4 |Cumulative percentage of patients receiving creatinine testing in the 12 months before end-stage renal disease, for
Medicare patients and patients in two private insurance registries. (Medstat and Ingenix i3).36
Table 1 | Nephrologist-dependent quality improvement processes to reduce catheter rates in incident patients
1 Discuss with referral sources criteria for referral (e.g., at a glomerular filtration rate (GFR) of p30ml/min).
2 Refer patients and families to educational classes about treatment options that should include peritoneal dialysis transplantation, etc., at GFR
p20min.
3 Explicitly discuss with patient and family the need for a permanent access at a GFR of p20ml/min.
4 a. Track success of surgical outcomes by surgeon.
b. Refer back to surgeon in 6–8 weeks if fistula is not maturing.
5 Provide full disclosure of catheter-related risks to patients (and families) who refuse surgery for permanent access.
6 Wearing of a medi-alert bracelet to protect one arm from venipuncture, peripherally inserted central catheters lines, etc.
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criteria for timely referral (e.g., GFR of p30 ml/min).
Because of the prevalence of patients in this GFR range,
nephrologists will often receive many referrals after such
hospital rounds, and efforts should be made to accommodate
appropriate referrals.
Although such guidance or GFR criteria needs to be
modulated with the age of the patient, and the inherent rate
of progression, a recent study has indicated that by
considering placement of permanent access at an estimated
GFR of 20 ml/min, even in patients aged 65–74 years old, the
ratio of ‘unnecessary’ to ‘necessary’ permanent access
(‘necessary’ meaning likely to be used within 2 years of
placement) is close to 1.0;39 moreover, the risks of fistula
placement, even if not needed for initiation of dialysis, are
much less than the morbidity and mortality risks of initiation
of dialysis with a catheter, consistent with the dictum that ‘it
may be better to die with an unused fistula than to die from a
used catheter.’40 The wearing of a medic-alert bracelet and the
timely placement of a permanent access, in patient with
advanced CKD, has the additional advantage of ‘protecting’
veins in the non-dominant arms that are often otherwise
cannulated (peripherally inserted central catheter ‘PICC’
lines) in the hospital setting. (Table 2) These GFR-based
guidelines also have the advantage of using objective criteria,
which can be explained ‘unemotionally’ to patients and
families independent of their symptoms, and is analogous to
aortic aneurysm resection, which is triggered by an
aneurismal dilatation of X5 cm, and which has resulted in
significant reduction of catastrophic aortic aneurysm rup-
ture.41 Ultimately, the goal of using this guideline is to reduce
the high percentages of patients initiating dialysis with a
catheter, particularly in those patients where the follow-up is
likely to be over several years, and the rate of regression is
relatively slow.
Permanent access placement as a pay for performance
measure
Making the percentage of patients initiating or being main-
tained on dialysis with a permanent access a ‘pay for
performance measure’ is in the best interest of the patient,
the caregivers, and the third party payer. Indeed, we would
argue that targeting a high percentage of hemodialysis patients
initiating hemodialysis with a functioning mature fistula as a
quality outcome goal might do more to improve hemodialysis
morbidity and mortality than all other implementable
interventions, and would likely simultaneously lead to
decreased overall health-care costs (Table 3). Data from the
USRDS suggest that differences in annual health-care costs,
Table 2 | Long-term initiatives to reduce catheter use and related morbidity
1 Encourage active discussions between nephrology organization (e.g., ASN, RPA, and NKF) and vascular surgical societies.
2 Devote specific NIH funds to study processes related to fistula failure such as neointimal hyperplasia.
3 National and local registry of permanent-access surgical outcomes.
4 Classify requests to hospitals for access placement as ‘urgent.’
5 Eliminate or reduce placement of peripherally inserted central catheters in hospitalized patients with abnormal creatinine or glomerular filtration
rate.
6 Sponsor large studies to reduce infections (e.g., antibacterial lock solutions), improve catheter patency in patients who cannot have a permanent
access.
7 Develop new materials or techniques to minimize graft thrombosis and primary fistula failure.
Table 3 | US-specific legislative/regulatory ‘call to action’ to reduce catheter rates in incident patients
1 Eliminate the 90-day waiting period for end-stage renal disease Medicare benefits for patients o65 years old.
2 Consider Medicare coverage for permanent access placement (and transplantation) for uninsured patients before dialysis initiation.
3 Develop a pay-for-performance metrics for surgeons and nephrologists for patients who initiate dialysis with a working permanent access.
4 Eliminate the 30-month limit to Medicare secondary payer provision.
5 Encourage/legislate that glomerular filtration rate be calculated for all measurement of creatinine by all laboratories.
Table 4 | Proposed pay-for-performance financial incentives
A. To the vascular surgeon:
1 $1000 for every patient who is initiated on dialysis with a working fistula (blood flow of 4500ml/min).
2 $500 for every patient who is initiated on dialysis with a healed graft (blood flow of 4800ml/min).
3 $500 for every patient who is initiated on dialysis with a functioning peritoneal dialysis (PD) catheter and an established arteriovenous (AV) fistula.
4 For patients with no insurance, but who are eligible for Medicare coverage 90 days after diagnosis of end-stage renal disease, add $500 to cover cost
of access procedures carried out before initiation of dialysis.
B. To the referring nephrologists:
1 $500 for every patient who is initiated on dialysis with a functioning permanent access.
2 $250 for every patient who acquires a permanent access (to replace a catheter) in the initial 90 days of dialysis.
C. To the dialysis unit:
1 $250 for every patient who is initiated on hemodialysis with a functioning permanent access and maintains access patency for X90 days.
2 $100 for every patient who is initiated on peritoneal dialysis with a functioning PD catheter and is peritonitis free for X90 days.
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including hospitalization and other outpatient (non-dialysis)
expenses for patients with catheters are, at least $20,000 higher
than the cost of patients with fistula.
A similar pay for performance measure is needed for
vascular surgeons for access placement. The amount of such a
‘pay for performance’ may be modulated depending on
whether the access is a fistula or a graft or even a PD catheter,
or more simply a ‘pay for performance’ for any initiation of
dialysis without a central catheter. A proposed scale for such
pay for performance is outlined in Table 4 for all those who
are directly involved in the formation and maintenance of a
functioning permanent access. The additional costs of such a
‘pay for performance’ is more than that made up by the
enormous savings ($20,000 ppt per year) that can be derived
from reduced hospitalizations associated with catheters.
Recently, the National Quality Forum has approved a time-
limited quality measure for kidney disease that is based on
measurement in patients with CKD stage 4 being seen and
evaluated (not just referred) by vascular surgeons for access
placement.
Although such ‘pay for performance’ may lead to the
placement of fistulas in patients who are not candidates for
dialysis, or who may receive transplantation before dialysis
initiation, we believe the risks of such ‘unintended con-
sequences’ are small and far outweighed by the benefits of
such a program.
Improved medical insurance coverage in CKD
The enormous costs associated with patients initiating
dialysis without a permanent access are well-known to the
Medicare Trust Fund; these range from multiple and often
prolonged hospital admissions for sepsis or infection,
including bacterial endocarditis, repeated thrombosis of
catheters requiring the use of expensive thrombolytic agents,
and the recurrent replacement of such catheters while
awaiting the eventual placement of a permanent access.
Although the recent MIPPA legislation includes provision
for the education of patients in CKD stages 4 and 5, what is
also urgently needed are provisions that allow for the
initiation of limited Medicare insurance coverage for patients
who do not have adequate insurance coverage that would
cover the costs of either pre-emptive kidney transplantation
or the placement of a permanent dialysis access when feasible.
Such a solution would eliminate the ‘wait and see’ response
by patients and surgeons for placement of an access until
such patients initiate dialysis (with a catheter) and have to
remain on dialysis for at least 90 days after dialysis initiation
to become ‘Medicare eligible.’ Considering that most such
patients will eventually be covered by Medicare and in the
interim, by Medicaid, at a much higher cost because of the
complications associated with catheters, it seems only
prudent to reduce such expenditures by ‘preventive’ insur-
ance coverage (Table 3).
The extent to which lack of insurance coverage has a role
in the high percentage (82%) of patients who initiate dialysis
with a catheter may be gleaned from a recent study of
Veterans Affairs patients (who generally have unrestricted
health insurance coverage), where in a cohort of approxi-
mately 3000 patients with estimated GFR of 18 ml/min per
1.73m2, 39% of the patients starting dialysis had undergone
surgery to place a permanent access beforehand.42 More
recently, the lack of adequate insurance was found to be a
statistically significant factor in patients having a fistula at the
time of dialysis initiation.40
‘Informed non-consent’
All medical interventions and procedures require the written
consent of patients. An unconventional and novel approach
that has been recently presented is the provision of ‘informed
non-consent’ for CKD patients who continue to delay or
refuse placement of a permanent access if they are
eligible.19,43 Such ‘informed non-consent,’ to be electively
signed by the patient and their next of kin would include the
risks of catheter placement and dialysis by a catheter, and
highlight the advantages of timely placement of permanent
access. This approach has been deemed an ‘ethical obligation’
of nephrologists.19 We also propose that studies be under-
taken to better understand the psychology of CKD patients
who refuse consent for timely placement of a permanent
access, so that such factors can be better addressed, in a way
that makes sense to the patient and their families.
Consensus development of expectations of vascular
surgeons
We suggest that the Society of Vascular Surgery (SVS)
develop a registration tool that would allow the identification
of surgical outcomes after attempts at permanent access
placement, and calculate national and regional outcomes of
such surgery; alternatively, CMS may make such outcomes
part of the ‘physician quality report’ as a first step to set
reasonable expectations of surgical outcomes (Table 2).
We would also suggest an ongoing dialogue between the
SVS and nephrology organizations such as the American
Society of Nephrology, the Renal Physician Association
(RPA) and others to highlight the need for vascular surgeons
(and hospitals) to consider permanent hemodialysis access as
an urgent priority, as well as emphasize the potential benefit
of vein mapping in all cases before surgery and evaluate the
outcomes of such procedures.23–25 Finally, a combined
recommendation to hospitals against routine placement of
‘PICC’ lines in any patient with a creatinine greater than
2 mg/dl or a GFR o30 ml/min would also be helpful. Such a
coordinated quality improvement project that involves the
hospital, the surgeon, and the nephrologist may well be
undertaken by the CMS-designated ‘Quality Improvement
Organization’ (QIO), which has administrative links to all
health-care organizations.
Mandatory calculation of GFR from serum creatinine
A number of states have legislatively imposed the require-
ments that laboratories calculate a GFR that is triggered when
a serum creatinine is requested by the physician. Although
1046 Kidney International (2009) 76, 1040–1048
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there has been resistance to having clinical laboratories report
‘un-measured’ or ‘calculated’ values, the potential societal
and health-care cost benefits of identifying patients with
advanced CKD should be obvious. Although there is still
some debate about the best method to calculate GFR, this
generally applies to the calculation of GFR above 40 or 50 ml/min
and may not be relevant to the identification and timely
referral of CKD stage 4 patients.
Additional research
Major factors in the high primary failure rates of fistulas and
the recurrent thromboses of grafts are stenoses, either at the
venous anastomosis or inflow artery. Recent work has
highlighted the important role of neointimal hyperplasia
resulting from the migration of fibroblasts from the
adventitia and bone marrow into the intima where these
cells acquire the phenotype of myofibroblasts.44,45 There is a
paucity of basic research in trying to understand the factors
that contribute to this transformation and even less clinical
research to identify the efficacy of therapies such as drug-
eluting devices (either as internal stents or parivascular cuffs),
radiation, cytoplast, or photodynamic therapies (Table 2).
In the recently reported NIH-funded Dialysis Access
Consortium randomized controlled trial of Aggrenox (long-
acting dipyridamole plus aspirin) versus placebo, Aggrenox
slightly (but statistically) reduced the risk of developing
stenosis and improved primary unassisted patency of newly
created grafts: in the Aggrenox-treated group, the primary
unassisted patency rate was only 28% at 1 year (versus 23%
in the placebo group.) Thus, the majority of new grafts either
thrombosed or required surgical or endovascular interven-
tion to maintain patency in a short-time frame, causing
substantial patient morbidity and costs.46,47 Although these
success rates are low (and much lower than those reported in
other countries),33,34 and indicate the need for repeat surgical
procedures, overall these risks are small relative to the risk of
catheter utilization. For established and functional accesses,
there are conflicting reports about the efficacy of prospective
surveillance and other technologies in prolonging access
lifetime.48–51 These limited studies point to the lack of a
‘magic bullet’ that is currently available to solve the vexing
issue of early access failure (fistulas and grafts) and highlight
the need not only to have a long time-line for permanent
access placement (e.g., 6 months) but for additional basic and
clinical research in this vitally important and expensive area
of nephrology.48
Strategies for late referrals
Undoubtedly, many patients will continue to be referred to
nephrology care very late in the course of CKD. As we and
others have advocated, use of a forearm graft with a
maturation of 2–3 weeks or peritoneal dialysis (even
intermittent nightly PD) may be in the best interest of these
late referral patients, compared with the outcome of patients
with catheters.11,35,49 Indeed, unless there is an urgency
because of severe electrolyte disorders, or florid pulmonary
edema that is poorly responsive to diuretics, a number of
nephrologists have advocated delaying any dialysis initiation
with a catheter, instead waiting out the maturation of a
permanent access. At a minimum, those who need to initiate
dialysis with a catheter need to have a permanent access
(fistula, graft, or PD) placed at the same time.
An ‘access coordinator’ in the dialysis facility
The type of access used by the patient is ultimately the
responsibility of the attending nephrologist. Nevertheless, the
designation of an ‘access coordinator’ in the dialysis facility
may help the identification of patients with catheters and the
need to review such a list at the Quality Assessment and
Process Improvement meeting, now mandated by the newly
promulgated CMS Conditions for Coverage. Such access
coordinators may also participate in the process of vein
mapping as well as in the referral to the vascular surgeon, and
track the periodic measurement of blood flow in permanent
access as a potential indication of impending thrombosis.50,51
Finally, the designation of specific caregivers at each facility
who, based on the record of their performance, are allowed to
cannulate new fistulas may help in reducing early fistula
failures. Such increased focus, time and effort by the dialysis
unit should also be a part of the ‘pay for performance’
(Table 4).
CONCLUSIONS
Many of the solutions presented here will require a concerted
effort from many entities and segments of health care, and
will require time for implementation. But concerted
solutions must be found to help reduce the rate of 82% of
patients who in 2007 started dialysis with a catheter. We owe
it to the patients entrusted to our care.
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